- Home
- TRVI vs XOMA Comparison
TRVI vs XOMA Comparison
Compare TRVI & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- XOMA
- Stock Information
- Founded
- TRVI 2011
- XOMA 1981
- Country
- TRVI United States
- XOMA United States
- Employees
- TRVI N/A
- XOMA N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- TRVI Health Care
- XOMA Health Care
- Exchange
- TRVI Nasdaq
- XOMA Nasdaq
- Market Cap
- TRVI 363.7M
- XOMA 319.3M
- IPO Year
- TRVI 2019
- XOMA N/A
- Fundamental
- Price
- TRVI $4.60
- XOMA $23.52
- Analyst Decision
- TRVI Strong Buy
- XOMA Strong Buy
- Analyst Count
- TRVI 8
- XOMA 2
- Target Price
- TRVI $9.31
- XOMA $72.00
- AVG Volume (30 Days)
- TRVI 739.7K
- XOMA 58.5K
- Earning Date
- TRVI 03-19-2025
- XOMA 03-07-2025
- Dividend Yield
- TRVI N/A
- XOMA N/A
- EPS Growth
- TRVI N/A
- XOMA N/A
- EPS
- TRVI N/A
- XOMA N/A
- Revenue
- TRVI N/A
- XOMA $21,606,000.00
- Revenue This Year
- TRVI N/A
- XOMA $511.37
- Revenue Next Year
- TRVI N/A
- XOMA $26.92
- P/E Ratio
- TRVI N/A
- XOMA N/A
- Revenue Growth
- TRVI N/A
- XOMA 389.82
- 52 Week Low
- TRVI $2.30
- XOMA $21.27
- 52 Week High
- TRVI $5.05
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- TRVI 62.80
- XOMA 33.53
- Support Level
- TRVI $3.93
- XOMA $24.01
- Resistance Level
- TRVI $4.14
- XOMA $27.43
- Average True Range (ATR)
- TRVI 0.29
- XOMA 1.15
- MACD
- TRVI 0.06
- XOMA -0.22
- Stochastic Oscillator
- TRVI 64.82
- XOMA 0.00
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.